$EVLO News
Last published 2y ago
- 2y agoAPREOMTHNRGMEDX+11Alltrna Announces Updates to Its Board of DirectorsPR NewswireAlltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and...
- 3y agoEVLOEvelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisGlobeNewswire- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo
- 3y agoEVLOEvelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsGlobeNewswire– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance
- 3y agoEVLOEvelo Biosciences Closes $25.5 Million Private PlacementGlobeNewswireRestructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo
- 3y agoEVLOEvelo Biosciences Announces $25.5 Million Private PlacementGlobeNewswireCAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting
- 3y agoEVLOEvelo Biosciences Announces Reverse Stock Split EffectiveGlobeNewswire– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 – CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology
- 3y agoDNLIDVAEVLOFHTX+5Cellarity Appoints Dr. Gregory J. Moore to Board of DirectorsBusiness WireCellarity, a life sciences company founded by Flagship
- 3y agoDNLIEVLOFHTXMCRB+3Montai Health Adds Industry Leaders to its Board of DirectorsBusiness Wire- Michael Severino, M.D. and Andreas Fibig bring decades of drug development and commercialization leadership experience to Montai
- 3y agoDNLIEVLOFHTXMCRB+3Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryPR NewswireThe company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship,
- 3y agoEVLOEvelo Biosciences Provides Clinical UpdatesGlobeNewswire– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV candidate, EDP2939, in Phase
- 3y agoDNLIEVLOFHTXIMPL+6Cellarity Strengthens Executive Leadership TeamBusiness WireCellarity, a life sciences company founded by Flagship
- 3y agoEVLOEvelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewswireCAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered
- 3y agoEVLOEvelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023GlobeNewswireCAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting
- 3y agoDNLIEVLOFHTXMCRB+3Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That Are Programed to Act Only Where NeededBusiness WireThe Company's Proprietary Address, Navigate, Design (AND)™ Platform Produces Medicines that are Better, Safer and More Tolerable for Patients
- 3y agoEVLOEvelo Biosciences to Participate in the Cowen 43rd Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on
- 3y agoEVLOEvelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis TrialGlobeNewswire– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated – – EDP2939
- 3y agoCRLDNLIEVLOFHTX+4Charles River and Flagship's Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical NeedsBusiness WireLogica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets
- 3y agoEVLOEvelo Biosciences Provides Clinical and Business UpdatesGlobeNewswire– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –– Clear path to registration trials for EDP1815 in psoriasis
- 3y agoEVLOEvaluation of the Immunopharmacology of EDP1815 and EDP2939 - NCT05682222ClinicalTrials.govKLH-induced immune reaction., KLH-induced immune reaction - basal flow., KLH-induced immune reaction - flare., (and 11 more...)
- 3y agoEVLOHRZNHorizon Technology Finance Provides Fourth Quarter 2022 Portfolio UpdatePR Newswire- Horizon Platform Originates $114 Million of New Loans in Q4, Including $104 Million of New Loans for HRZN - - HRZN Grows Loan Portfolio by $262 Million in 2022 -- Horizon Platform Ends 2022 with Committed Backlog of
- 3y agoEVLOHRZNEvelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing DebtGlobeNewswireCAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal
- 3y agoEVLOEvelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in ImmunologyGlobeNewswirePeer-reviewed article explains the immunology of the small intestinal axisCompany to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) --
- 3y agoEVLOEvelo Biosciences Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewswire- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first extracellular vesicle
- 4y agoEVLOEvelo Biosciences to Present at the 2022 Jefferies London Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal
- 4y agoDNLIEVLOFHTXMCRB+4Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery PlatformPR NewswireDr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology
- 4y agoDNLIEVLOFHTXMCRB+4Cellarity Announces Close of $121 Million Series C FinancingBusiness WireCellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to
- 4y agoEVLOEvelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) CongressGlobeNewswireCAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented bi
- 4y agoEVLOEvelo Biosciences Announces Grant of Inducement AwardGlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced th
- 4y agoEVLOEvelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced th
- 4y agoDNLIEVLOFHTXMCRB+4Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell BehaviorBusiness WireThe dataset will be publicly available for a Kaggle competition presented at NeurIPS 2022 hosted by Open Problems in Single-Cell Analysis in collaboration with Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, Yale University, and Helmholtz Munich
- 4y agoDNLIEVLOFHTXMCRB+4Senda Biosciences Announces Close of $123 Million Series C FinancingPR NewswireCAMBRIDGE, Mass., Aug. 16, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the completion of a $123 million Series C financing, bringing its total fu
- 4y agoEVLOEvelo Biosciences Announces Succession PlanGlobeNewswire– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart for Chief Executive Officer search – CAMBRIDGE, Mass., Aug. 11, 2022
- 4y agoEVLOEvelo Biosciences Announces Second Quarter 2022 Financial Results and Business HighlightsGlobeNewswire– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase 2 data for EDP2939 in psoriasis expected in
- 4y agoEVLOEvelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsEVLO earnings call for the period ending June 30, 2022.
- 4y agoEVLOEvelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022GlobeNewswireCAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced tha
- 4y agoEVLOEvelo Biosciences Announces Appointment of Marella Thorell as Chief Financial OfficerGlobeNewswireCAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced the
- 4y agoEVLOA Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials - NCT05439941ClinicalTrials.govIncidence and rate per 100 patient-years of treatment-emergent adverse events, Percentage of participants achieving EASI-50, Percentage of participants achieving EASI-75, (and 32 more...)
- 4y agoEVLOZYMECytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product OfficerPR NewswireAVENTURA, Fla. and NATICK, Mass., June 7, 2022 /PRNewswire/ -- Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on empowering natural killer (NK) cells to fight cancer through multispecific antibodies and st
- 4y agoDNLIEVLOFHTXMCRB+4Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive OfficerBusiness WireFlagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined Tessera as Chief Executive Officer. Dr. Severino, wh
- 4y agoDNLIEVLOFHTXMCRB+4Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New MedicinesBusiness WireThe Company's ProFoundry™ Platform has to date identified tens of thousands of previously undiscovered proteins that represent a vastly expanded number of therapeutic targets Flagship commits $75 million to enable the continued expansion of the
- 4y agoEVLOEvelo Biosciences Announces $79.2 Million Registered Direct Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agr
- 4y agoEVLOEvelo Biosciences Announces First Quarter 2022 Financial Results and Business HighlightsGlobeNewswireCAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the f
- 4y agoEVLOEvelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic AdvisorsGlobeNewswireCAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that John Maraganore, Ph.D., founder and longtim
- 4y agoAXLACDAKDNLIEVLO+7Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING PlatformBusiness WireLatest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine
- 4y agoEVLOEvelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation ProgramsGlobeNewswire–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release capsule cohort to be added to on-going Phase 2
- 4y agoAXLACDAKDNLIEVLO+7Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of AlltrnaPR NewswireWerner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team w
- 4y agoEVLOEvelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Jose-Carlos Gutiérrez-Ramo
- 4y agoEVLOEvelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual MeetingGlobeNewswireCAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented
- 4y agoEVLOEvelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business HighlightsGlobeNewswire–Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 ––Positive data reported on faster release capsule––Phase 2 data from EDP1815 in atopic dermatitis on-track fo
- 4y agoEVLOEvelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsEVLO earnings call for the period ending December 31, 2021.